



Clinical trial results:

A Phase I, double-blind, randomised, placebo controlled study to evaluate the reactogenicity and safety of a single oral dose of GlaxoSmithKline (GSK) Biologicals' live attenuated liquid human rotavirus (HRV) vaccine in healthy children aged 2 to 6 years in China.

Summary

EudraCT number	2015-001547-37
Trial protocol	Outside EU/EEA
Global end of trial date	16 April 2010

Results information

Result version number	v1 (current)
This version publication date	20 April 2016
First version publication date	17 July 2015

Trial information

Trial identification

Sponsor protocol code	113552
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01086436
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalsupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalsupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 July 2010
Is this the analysis of the primary completion data?	Yes
Primary completion date	16 April 2010
Global end of trial reached?	Yes
Global end of trial date	16 April 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the reactogenicity of a single oral dose of GSK Biologicals' liquid HRV vaccine when compared to placebo group, in terms of solicited AEs in healthy children aged 2 to 6 years

Protection of trial subjects:

The subjects were observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of anaphylaxis following the administration of the vaccine.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 March 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	China: 50
Worldwide total number of subjects	50
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	50
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	HRV Group

Arm description:

Subjects received a single oral dose of GSK Biologicals' oral live attenuated liquid human rotavirus vaccine (HRV) vaccine at Day 0

Arm type	Experimental
Investigational medicinal product name	Rotarix
Investigational medicinal product code	
Other name	HUMAN ROTAVIRUS RIX4414 STRAIN (LIVE ATTENUATED)
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use

Dosage and administration details:

One dose of HRV vaccine administered orally at Day 0.

Arm title	Placebo Group
------------------	---------------

Arm description:

Subjects received a single oral dose of placebo at Day 0

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Oral use

Dosage and administration details:

One dose of placebo administered orally at Day 0

Number of subjects in period 1	HRV Group	Placebo Group
Started	25	25
Completed	25	25

Baseline characteristics

Reporting groups

Reporting group title	HRV Group
Reporting group description: Subjects received a single oral dose of GSK Biologicals' oral live attenuated liquid human rotavirus vaccine (HRV) vaccine at Day 0	
Reporting group title	Placebo Group
Reporting group description: Subjects received a single oral dose of placebo at Day 0	

Reporting group values	HRV Group	Placebo Group	Total
Number of subjects	25	25	50
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	3.7	3.9	
standard deviation	± 0.89	± 0.97	-
Gender categorical Units: Subjects			
Female	9	16	25
Male	16	9	25

End points

End points reporting groups

Reporting group title	HRV Group
Reporting group description:	
Subjects received a single oral dose of GSK Biologicals' oral live attenuated liquid human rotavirus vaccine (HRV) vaccine at Day 0	
Reporting group title	Placebo Group
Reporting group description:	
Subjects received a single oral dose of placebo at Day 0	

Primary: Number of subjects reporting any, grade 3 and related solicited general symptoms

End point title	Number of subjects reporting any, grade 3 and related solicited general symptoms ^[1]
-----------------	---

End point description:

Assessed solicited general symptoms were cough, diarrhea, irritability, loss of appetite, fever (According to Chinese scale and GSK scale) and vomiting.

Any = occurrence of the symptom regardless of intensity grade or relationship to study vaccination.

Grade 3 Cough = Cough/runny nose which prevented daily activity. Grade 3 Diarrhea = ≥ 6 looser than normal stools/day. Grade 3 Irritability = Crying that could not be comforted/ prevented normal activity. Grade 3 Loss of appetite = Did not eat at all. Grade 3 fever (axillary temperature) = $>39.0^{\circ}\text{C}$ according to both the Chinese and GSK scales. Grade 3 Vomiting = ≥ 3 episodes of vomiting/day. Related = symptom assessed by the investigator as related to the vaccination.

End point type	Primary
----------------	---------

End point timeframe:

During the 8-day (Days 0-7) post-vaccination period

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed

End point values	HRV Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	25		
Units: Subjects				
Any Cough	10	12		
Grade 3 Cough	0	0		
Related Cough	0	1		
Any Diarrhea	1	1		
Grade 3 Diarrhea	0	1		
Related Diarrhea	1	0		
Any Irritability	3	2		
Grade 3 Irritability	0	0		
Related Irritability	0	0		
Any Loss of appetite	2	3		
Grade 3 Loss of appetite	0	0		
Related Loss of appetite	0	0		
Any temperature (Chinese scale)	4	5		
Grade 3 temperature (Chinese scale)	0	0		

Related temperature (Chinese scale)	0	1		
Any temperature (GSK scale)	1	2		
Grade 3 temperature (GSK scale)	0	0		
Related temperature (GSK scale)	0	1		
Any Vomiting	1	0		
Grade 3 Vomiting	0	0		
Related Vomiting	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse event (AE)

End point title	Number of subjects reporting any unsolicited adverse event (AE)
-----------------	---

End point description:

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study period of one month (Day 0 – Day 30). Also, any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 31 days (Day 0 - Day 30) after the HRV vaccine/placebo dose

End point values	HRV Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	25		
Units: Subjects				
Any AE(s)	11	13		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs)
-----------------	---

End point description:

Serious adverse events (SAEs) assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Month 1)

End point values	HRV Group	Placebo Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	25		
Units: Subjects				
Any SAE(s)	0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms were collected during the 8-day (Days 0-7) post vaccination period. Unsolicited AEs were collected during the 31-day (Days 0-30) post vaccination period. SAEs were collected during the entire study period (Day 0 - Month 1).

Adverse event reporting additional description:

The number of occurrences reported for solicited symptoms, adverse events, and serious adverse events were not available for posting. The number of subjects affected by each specific event was indicated as the number of occurrences.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.0
--------------------	------

Reporting groups

Reporting group title	HRV Group
-----------------------	-----------

Reporting group description:

Subjects received a single oral dose of GSK Biologicals' oral live attenuated liquid human rotavirus vaccine (HRV) vaccine at Day 0

Reporting group title	Placebo Group
-----------------------	---------------

Reporting group description:

Subjects received a single oral dose of placebo at Day 0

Serious adverse events	HRV Group	Placebo Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	HRV Group	Placebo Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 25 (100.00%)	25 / 25 (100.00%)	
General disorders and administration site conditions			
Cough (solicited)			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 25 (40.00%)	12 / 25 (48.00%)	
occurrences (all)	10	12	
Diarrhea			

alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	1 / 25 (4.00%) 1	
Irritability alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 25 (12.00%) 3	2 / 25 (8.00%) 2	
Loss of appetite alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2	3 / 25 (12.00%) 3	
Fever (Chinese scale) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	4 / 25 (16.00%) 4	5 / 25 (20.00%) 5	
Fever (GSK scale) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	2 / 25 (8.00%) 2	
Pyrexia subjects affected / exposed occurrences (all)	3 / 25 (12.00%) 3	1 / 25 (4.00%) 1	
Respiratory, thoracic and mediastinal disorders Cough (unsolicited) subjects affected / exposed occurrences (all)	3 / 25 (12.00%) 3	5 / 25 (20.00%) 5	
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	2 / 25 (8.00%) 2	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	3 / 25 (12.00%) 3	4 / 25 (16.00%) 4	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported